Stanford University
Constance R. Chu, MD
Patients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and reconstructive surgery reduces inflammation and improves joint health as a new strategy to prevent or delay the onset of PTOA.
Anterior Cruciate Ligament Reconstruction
Tranexamic Acid
Placebos
PHASE2
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 50 participants |
| Masking : | QUADRUPLE |
| Masking Description : | double blinded RCT |
| Primary Purpose : | TREATMENT |
| Official Title : | Novel Strategies to Combat Post-Traumatic Osteoarthritis (PTOA):The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients |
| Actual Study Start Date : | 2019-08-01 |
| Estimated Primary Completion Date : | 2025-01-14 |
| Estimated Study Completion Date : | 2025-01-14 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 30 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Stanford University
Stanford, California, United States, 94305